Aster DM Q4 FY26: Revenue up 18% to ₹1,182 Cr, EBITDA up 31%, merger advances

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

ASTERDM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.8%Reaction day

₹707.00

prior close

₹725.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%+3.8% vs market

Hospital peers, median of 23sector+2.0%+2.8% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Smallcap 250 and 2.8 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.8

10m

+4.0

15m

+4.6

30m

+2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.8+1.0+3.8+2.0+2.8

Next day

+5.2+1.2+4.0+1.7+3.5

+3.5+3.0+0.5+2.7+0.8

+5.0+4.1+0.9+3.2+1.8

+5.0+4.2+0.7+4.9+0.0

+4.5+3.1+1.4+5.6-1.1

+4.1+0.3+3.8+3.0+1.0

15d

+5.0+1.5+3.5+5.4-0.4

+4.5+1.9+2.6+6.1-1.6

+11.6+8.1+3.5+7.6+4.0

+17.4+8.7+8.7+8.5+8.9

UpDownMarket · Nifty Smallcap 250Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aster DM Q4 FY26: Revenue up 18% YoY to ₹1,182 Cr. Operating EBITDA (ex-Kasaragod) rose 31% to ₹253 Cr; margins expanded to 21.7% from 19.3%. Normalised PAT (ex-Kasaragod) up 45% to ₹153 Cr. Proforma combined with QCIL: Revenue ₹2,361 Cr (+18%), EBITDA ₹517 Cr (+25%). Patient volumes grew 15%. Merger with Quality Care India got 96.68% shareholder approval; CCI approval received, NCLT order pending. Expected to close Q1 FY27, creating a 10,623+ bed platform across 28 cities.

Likely market impact

Strong Q4 with double-digit revenue and EBITDA growth, margin expansion, and major merger with QCIL nearing completion — positive for growth and scale.